Vagus nerve stimulation (implanted and transcutaneous auricular)

Domain IX · Biomedical, neuro & digital · 1997 · USA

What it is

Vagus nerve stimulation (VNS) delivers mild electrical pulses to the vagus nerve, the long cranial nerve that runs from the brainstem through the neck to the heart, lungs and gut. It comes in three quite different forms, and clients often run them together:

Format

• Implanted VNS, epilepsy: labelled as add-on therapy to reduce seizure frequency in people aged 4 years and older with partial-onset (focal) seizures that do not respond to antiseizure medicines. Medicare has covered VNS for medically refractory partial-onset seizures, where surgery is not…
• Implanted VNS, depression: FDA premarket approval in 2005 for adjunctive long-term treatment of chronic or recurrent depression in adults (18+) in a major depressive episode who have not responded adequately to four or more antidepressant treatments.

Who practises it, and how they are trained or regulated

• An auricular device from tVNS Technologies (Erlangen), "tVNS E", is described by its regional industry network as a class IIa medical device certified under the EU Medical Device Regulation (2017/745), with a wide list of stated indications including depression, anxiety disorders, epilepsy, migraine and sleep disorders. This is the company's own description as relayed by that network (page last modified May 2025),…
• Lightly regulated; some companies avoid FDA review by making vague wellness claims (energy, sleep, memory) rather than disease claims. Researchers quoted in reporting say there is little or no data that consumer gadgets work, that skin tingling or heart-rate changes are not evidence of vagus nerve effects, and that the main harm is false hope and delayed effective treatment. Treat these claims as contested and…
• Version followed: implanted VNS as described in the US manufacturer's patient safety information for epilepsy and depression (LivaNova, VNS Therapy), NICE interventional procedures guidance IPG679 (August 2020, which replaced IPG330) and CMS National Coverage Determination 160.18 (version effective 15 February 2019); non-invasive VNS as described in the gammaCore labelling summary and FDA 510(k) records; consumer…

Evidence status, as the guide reports it

• Medicare coverage for depression: since 15 February 2019, CMS covers FDA-approved VNS for treatment-resistant depression only under Coverage with Evidence Development, i.e. within a CMS-approved, double-blind, randomised, placebo-controlled trial with at least one year of follow-up. The approved…

Questions to explore with your client

• What drew you to it, and what are you hoping it will change?
• Is there physical contact? Was it explained beforehand, and do you feel free to say no or stop at any point?
• Does it involve any substance, plant preparation, remedy or supplement? Has your doctor or prescriber been told, especially about any medication you take?
• Does it involve intense or unusual breathing? Have you been told about the medical conditions for which that is not advised?
• Does it involve fasting, a special diet or 'detox'? Have you discussed this with your doctor?
• Who runs it, and what training or registration do they hold?
• What actually happens in a session or meeting, and how often?
• What does it cost, and is there pressure to commit to more?
• How do you feel afterwards, in the hours and days that follow?
• Does it fit with, or clash with, the work we do here?

What practitioners of it watch for

• sharp rise in hopelessness. Working if: the client stays engaged with care.
• physiotherapy heat treatments and scans being arranged without the team's knowledge.
• fragmented care across neurology, psychiatry and surgery. Working if: reports reach the right clinician on time.
• demoralisation and hopelessness feeding risk. Working if: concerns reach the team and the client feels less alone with them.
• information overload in depressed clients; repeat and write down key points. Working if: the client can name what VNS is for and what it is not.

When to involve someone else

• New or worsening physical symptoms, or advice to stop or change prescribed medication: involve the client's doctor or prescriber.
• Signs of coercion, isolation from family and friends, escalating costs or secrecy: discuss openly and consider safeguarding.
• A crisis or thoughts of suicide: follow your crisis protocol. In the US, call or text 988; in the UK and Ireland, Samaritans on 116 123.

Drawn automatically from the guide's own sections. Stay curious: neither endorse nor dismiss what the client values, and check anything that matters against the full guide and its sources. Not medical advice.